Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Epothilones
  • Lymphoma, Non-Hodgkin
  • Tubulin Modulators

abstract

  • The recommended dose of ixabepilone for the initiation of phase II studies on the basis of these results is 50 mg/m2 over 1 hour every 3 weeks. The promising efficacy and tolerability results demonstrated by ixabepilone in this study warrant its continued development.

publication date

  • March 20, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.2006.08.7304

PubMed ID

  • 17261851

Additional Document Info

start page

  • 1082

end page

  • 8

volume

  • 25

number

  • 9